The global intravenous immunoglobulin market size was valued at US$ 9,353.5 Mn in 2018 and is projected to expand at a CAGR of 8.1% from 2019 to 2026. Rapid innovation in and development of blood plasma derived products have enabled physicians across the globe to achieve timely and adequate disease management, thereby providing superior quality patient care. The global intravenous immunoglobulin market is expected to witness robust growth in the near future due to rise in prevalence of autoimmune disorders, increase in the global geriatric population, surge in IVIG usage in off-label indications, high demand for more reliable and adequate treatment measures, and increase in incidence of various hematological and neurological disorders. Moreover, improved technology for production and purification methods have fueled demand for IVIG.
The report analyzes and forecasts the intravenous immunoglobulin market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of intravenous immunoglobulin, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major intravenous immunoglobulin companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of intravenous immunoglobulin upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of intravenous immunoglobulin and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global intravenous immunoglobulin market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the intravenous immunoglobulin market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of intravenous immunoglobulin market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Competitive Landscape
The report also profiles major players in the global intravenous immunoglobulin market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the global intravenous immunoglobulin market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities undertaken by the major players. Key companies profiled in the report include Shire plc, ADMA Biologics, Inc., China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.
The global intravenous immunoglobulin market has been segmented as follows:
Global Intravenous immunoglobulin Market, by Indication
Global Intravenous Immunoglobulin Market, by End-user
Global Intravenous Immunoglobulin Market, by Region
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Section 1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
Section 2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
Section 3. Executive Summary
3.1. Global Intravenous Immunoglobulin (IVIG): Market Snapshot
3.2. Market Share Analysis, by Region, 2017
3.3. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map
Section 4. Market Overview
4.1. Indication Overview
4.2. Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments
4.3. Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators
Section 5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Rise in prevalence of autoimmune disorders
5.2.2. Increase in global geriatric population
5.2.3. Growing usage in off-label indications
5.2.4. Improved technology for production and purification methods
5.2.5. Favorable government initiatives and approvals
5.2.6. Increase in health care spending & improving health care infrastructure
5.2.7. Rise in incidence of hematological, neurological disorders
5.3. Restraints
5.3.1. High cost of treatment
5.3.2. Chronic side effects
5.3.3. Supply demand gaps
5.3.4. Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications
5.4. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis
5.5. Opportunities
5.5.1. Application in newer indications
5.5.2. Increasing global plasma yield to offer significant opportunities to new entrants
5.6. Key Trends
5.7. Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2026
5.8. Value Chain Analysis
5.9. Global Intravenous Immunoglobulin (IVIG) Market Outlook
Section 6. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.1. Key Findings
6.2. Introduction
6.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication
6.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6.4.2. Primary Humoral Immunodeficiency
6.4.3. Idiopathic Thrombocytopenic Purpura (ITP)
6.4.4. Guillain-Barre Syndrome
6.4.5. Myasthenia Gravis
6.4.6. Multifocal Motor Neuropathy (MMN)
6.4.7. Kawasaki Disease
6.4.8. Hypogammaglobulinemia
6.4.9. Chronic Lymphocytic Leukemia
6.4.10. Others
6.5. Market Attractiveness Analysis, by Indication
6.6. Key Trends
Section 7. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.1. Key Findings
7.2. Introduction
7.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user
7.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.4.1. Hospitals
7.4.2. Clinics
7.4.3. Home Care
7.5. Market Attractiveness Analysis, by End-user
7.6. Key Trends
Section 8. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Region
8.1. Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country
8.2. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region
8.3. Intravenous Immunoglobulin (IVIG) Market Forecast, by Region
8.4. Market Attractiveness Analysis, by Region
Section 9. North America Intravenous Immunoglobulin (IVIG) Market Analysis
9.1. Key Findings
9.2. Market Overview
9.3. Market Analysis, by Indication
9.3.1. Market Value Share Analysis, by Indication
9.3.2. Market Size (US$ Mn) Forecast, by Indication
9.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.3.2.2. Primary Humoral Immunodeficiency
9.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.3.2.4. Guillain-Barre Syndrome
9.3.2.5. Myasthenia Gravis
9.3.2.6. Multifocal Motor Neuropathy (MMN)
9.3.2.7. Kawasaki Disease
9.3.2.8. Hypogammaglobulinemia
9.3.2.9. Chronic Lymphocytic Leukemia
9.3.2.10. Others
9.4. Market Analysis, by End-user
9.4.1. Market Value Share Analysis, by End-user
9.4.2. Market Size (US$ Mn) Forecast, by End-user
9.4.2.1. Hospitals
9.4.2.2. Clinics
9.4.2.3. Home Care
9.5. Market Analysis, by Country
9.5.1. Market Value Share Analysis, by Country
9.5.2. Market Size (US$ Mn) Forecast, by Country, 2018–2026
9.5.2.1. U.S.
9.5.2.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Indication
9.6.2. By End-user
9.6.3. By Country
9.7. U.S. Intravenous Immunoglobulin (IVIG) Market Analysis
9.7.1. Market Size (US$ Mn) Forecast, by Indication
9.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.7.1.2. Primary Humoral Immunodeficiency
9.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.7.1.4. Guillain-Barre Syndrome
9.7.1.5. Myasthenia Gravis
9.7.1.6. Multifocal Motor Neuropathy (MMN)
9.7.1.7. Kawasaki Disease
9.7.1.8. Hypogammaglobulinemia
9.7.1.9. Chronic Lymphocytic Leukemia
9.7.1.10. Others
9.7.2. Market Size (US$ Mn) Forecast, by End-user
9.7.2.1. Hospitals
9.7.2.2. Clinics
9.7.2.3. Home Care Settings
9.8. Canada Intravenous Immunoglobulin (IVIG) Market Analysis
9.8.1. Market Size (US$ Mn) Forecast, by Indication
9.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.8.1.2. Primary Humoral Immunodeficiency
9.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.8.1.4. Guillain-Barre Syndrome
9.8.1.5. Myasthenia Gravis
9.8.1.6. Multifocal Motor Neuropathy (MMN)
9.8.1.7. Kawasaki Disease
9.8.1.8. Hypogammaglobulinemia
9.8.1.9. Chronic Lymphocytic Leukemia
9.8.1.10. Others
9.8.2. Market Size (US$ Mn) Forecast, by End-user
9.8.2.1. Hospitals
9.8.2.2. Clinics
9.8.2.3. Home Care Settings
Section 10. Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.1. Key Findings
10.2. Market Overview
10.3. Market Analysis, by Indication
10.3.1. Market Value Share Analysis, by Indication
10.3.2. Market Size (US$ Mn) Forecast, by Indication
10.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.3.2.2. Primary Humoral Immunodeficiency
10.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.3.2.4. Guillain-Barre Syndrome
10.3.2.5. Myasthenia Gravis
10.3.2.6. Multifocal Motor Neuropathy (MMN)
10.3.2.7. Kawasaki Disease
10.3.2.8. Hypogammaglobulinemia
10.3.2.9. Chronic Lymphocytic Leukemia
10.3.2.10. Others
10.4. Market Analysis, by End-user
10.4.1. Market Value Share Analysis, by End-user
10.4.2. Market Size (US$ Mn) Forecast, by End-user
10.4.2.1. Hospitals
10.4.2.2. Clinics
10.4.2.3. Home Care
10.5. Market Analysis, by Country/Sub-region
10.5.1. Market Value Share Analysis, by Country
10.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
10.5.2.1. U.K.
10.5.2.2. Germany
10.5.2.3. France
10.5.2.4. Spain
10.5.2.5. Italy
10.5.2.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Indication
10.6.2. By End-user
10.6.3. By Country/Sub-region
10.7. U.K. Intravenous Immunoglobulin (IVIG) Market Analysis
10.7.1. Market Size (US$ Mn) Forecast, by Indication
10.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.7.1.2. Primary Humoral Immunodeficiency
10.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.7.1.4. Guillain-Barre Syndrome
10.7.1.5. Myasthenia Gravis
10.7.1.6. Multifocal Motor Neuropathy (MMN)
10.7.1.7. Kawasaki Disease
10.7.1.8. Hypogammaglobulinemia
10.7.1.9. Chronic Lymphocytic Leukemia
10.7.1.10. Others
10.7.2. Market Size (US$ Mn) Forecast, by End-user
10.7.2.1. Hospitals
10.7.2.2. Clinics
10.7.2.3. Home Care Settings
10.8. Germany Intravenous Immunoglobulin (IVIG) Market Analysis
10.8.1. Market Size (US$ Mn) Forecast, by Indication
10.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.8.1.2. Primary Humoral Immunodeficiency
10.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.8.1.4. Guillain-Barre Syndrome
10.8.1.5. Myasthenia Gravis
10.8.1.6. Multifocal Motor Neuropathy (MMN)
10.8.1.7. Kawasaki Disease
10.8.1.8. Hypogammaglobulinemia
10.8.1.9. Chronic Lymphocytic Leukemia
10.8.1.10. Others
10.8.2. Market Size (US$ Mn) Forecast, by End-user
10.8.2.1. Hospitals
10.8.2.2. Clinics
10.8.2.3. Home Care Settings
10.9. France Intravenous Immunoglobulin (IVIG) Market Analysis
10.9.1. Market Size (US$ Mn) Forecast, by Indication
10.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.9.1.2. Primary Humoral Immunodeficiency
10.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.9.1.4. Guillain-Barre Syndrome
10.9.1.5. Myasthenia Gravis
10.9.1.6. Multifocal Motor Neuropathy (MMN)
10.9.1.7. Kawasaki Disease
10.9.1.8. Hypogammaglobulinemia
10.9.1.9. Chronic Lymphocytic Leukemia
10.9.1.10. Others
10.9.2. Market Size (US$ Mn) Forecast, by End-user
10.9.2.1. Hospitals
10.9.2.2. Clinics
10.9.2.3. Home Care Settings
10.10 Spain Intravenous Immunoglobulin (IVIG) Market Analysis
10.10.1. Market Size (US$ Mn) Forecast, by Indication
10.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.10.1.2. Primary Humoral Immunodeficiency
10.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.10.1.4. Guillain-Barre Syndrome
10.10.1.5. Myasthenia Gravis
10.10.1.6. Multifocal Motor Neuropathy (MMN)
10.10.1.7. Kawasaki Disease
10.10.1.8. Hypogammaglobulinemia
10.10.1.9. Chronic Lymphocytic Leukemia
10.10.1.10. Others
10.10.2. Market Size (US$ Mn) Forecast, by End-user
10.10.2.1. Hospitals
10.10.2.2. Clinics
10.10.2.3. Home Care Settings
10.11 Italy Intravenous Immunoglobulin (IVIG) Market Analysis
10.11.1. Market Size (US$ Mn) Forecast, by Indication
10.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.11.1.2. Primary Humoral Immunodeficiency
10.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.11.1.4. Guillain-Barre Syndrome
10.11.1.5. Myasthenia Gravis
10.11.1.6. Multifocal Motor Neuropathy (MMN)
10.11.1.7. Kawasaki Disease
10.11.1.8. Hypogammaglobulinemia
10.11.1.9. Chronic Lymphocytic Leukemia
10.11.1.10. Others
10.11.2. Market Size (US$ Mn) Forecast, by End-user
10.11.2.1. Hospitals
10.11.2.2. Clinics
10.11.2.3. Home Care Settings
10.12 Rest of Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.12.1. Market Size (US$ Mn) Forecast, by Indication
10.12.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.12.1.2. Primary Humoral Immunodeficiency
10.12.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.12.1.4. Guillain-Barre Syndrome
10.12.1.5. Myasthenia Gravis
10.12.1.6. Multifocal Motor Neuropathy (MMN)
10.12.1.7. Kawasaki Disease
10.12.1.8. Hypogammaglobulinemia
10.12.1.9. Chronic Lymphocytic Leukemia
10.12.1.10. Others
10.12.2. Market Size (US$ Mn) Forecast, by End-user
10.12.2.1. Hospitals
10.12.2.2. Clinics
10.12.2.3. Home Care Settings
Section 11. Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.1. Key Findings
11.2. Market Overview
11.3. Market Analysis, by Indication
11.3.1. Market Value Share Analysis, by Indication
11.3.2. Market Size (US$ Mn) Forecast, by Indication
11.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.3.2.2. Primary Humoral Immunodeficiency
11.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.3.2.4. Guillain-Barre Syndrome
11.3.2.5. Myasthenia Gravis
11.3.2.6. Multifocal Motor Neuropathy (MMN)
11.3.2.7. Kawasaki Disease
11.3.2.8. Hypogammaglobulinemia
11.3.2.9. Chronic Lymphocytic Leukemia
11.3.2.10. Others
11.4. Market Analysis, by End-user
11.4.1. Market Value Share Analysis, by End-user
11.4.2. Market Size (US$ Mn) Forecast, by End-user
11.4.2.1. Hospitals
11.4.2.2. Clinics
11.4.2.3. Home Care
11.5. Market Analysis, by Country/Sub-region
11.5.1. Market Value Share Analysis, by Country
11.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
11.5.2.1. China
11.5.2.2. Japan
11.5.2.3. Australia
11.5.2.4. India
11.5.2.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Indication
11.6.2. By End-user
11.6.3. By Country/Sub-region
11.7. China Intravenous Immunoglobulin (IVIG) Market Analysis
11.7.1. Market Size (US$ Mn) Forecast, by Indication
11.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.7.1.2. Primary Humoral Immunodeficiency
11.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.7.1.4. Guillain-Barre Syndrome
11.7.1.5. Myasthenia Gravis
11.7.1.6. Multifocal Motor Neuropathy (MMN)
11.7.1.7. Kawasaki Disease
11.7.1.8. Hypogammaglobulinemia
11.7.1.9. Chronic Lymphocytic Leukemia
11.7.1.10. Others
11.7.2. Market Size (US$ Mn) Forecast, by End-user
11.7.2.1. Hospitals
11.7.2.2. Clinics
11.7.2.3. Home Care Settings
11.8. Japan Intravenous Immunoglobulin (IVIG) Market Analysis
11.8.1. Market Size (US$ Mn) Forecast, by Indication
11.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.8.1.2. Primary Humoral Immunodeficiency
11.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.8.1.4. Guillain-Barre Syndrome
11.8.1.5. Myasthenia Gravis
11.8.1.6. Multifocal Motor Neuropathy (MMN)
11.8.1.7. Kawasaki Disease
11.8.1.8. Hypogammaglobulinemia
11.8.1.9. Chronic Lymphocytic Leukemia
11.8.1.10. Others
11.8.2. Market Size (US$ Mn) Forecast, by End-user
11.8.2.1. Hospitals
11.8.2.2. Clinics
11.8.2.3. Home Care Settings
11.9. Australia Intravenous Immunoglobulin (IVIG) Market Analysis
11.9.1. Market Size (US$ Mn) Forecast, by Indication
11.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.9.1.2. Primary Humoral Immunodeficiency
11.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.9.1.4. Guillain-Barre Syndrome
11.9.1.5. Myasthenia Gravis
11.9.1.6. Multifocal Motor Neuropathy (MMN)
11.9.1.7. Kawasaki Disease
11.9.1.8. Hypogammaglobulinemia
11.9.1.9. Chronic Lymphocytic Leukemia
11.9.1.10. Others
11.9.2. Market Size (US$ Mn) Forecast, by End-user
11.9.2.1. Hospitals
11.9.2.2. Clinics
11.9.2.3. Home Care Settings
11.10 India Intravenous Immunoglobulin (IVIG) Market Analysis
11.10.1. Market Size (US$ Mn) Forecast, by Indication
11.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.10.1.2. Primary Humoral Immunodeficiency
11.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.10.1.4. Guillain-Barre Syndrome
11.10.1.5. Myasthenia Gravis
11.10.1.6. Multifocal Motor Neuropathy (MMN)
11.10.1.7. Kawasaki Disease
11.10.1.8. Hypogammaglobulinemia
11.10.1.9. Chronic Lymphocytic Leukemia
11.10.1.10. Others
11.10.2. Market Size (US$ Mn) Forecast, by End-user
11.10.2.1. Hospitals
11.10.2.2. Clinics
11.10.2.3. Home Care Settings
11.11 Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.11.1. Market Size (US$ Mn) Forecast, by Indication
11.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.11.1.2. Primary Humoral Immunodeficiency
11.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.11.1.4. Guillain-Barre Syndrome
11.11.1.5. Myasthenia Gravis
11.11.1.6. Multifocal Motor Neuropathy (MMN)
11.11.1.7. Kawasaki Disease
11.11.1.8. Hypogammaglobulinemia
11.11.1.9. Chronic Lymphocytic Leukemia
11.11.1.10. Others
11.11.2. Market Size (US$ Mn) Forecast, by End-user
11.11.2.1. Hospitals
11.11.2.2. Clinics
11.11.2.3. Home Care Settings
Section 12. Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.1. Key Findings
12.2. Market Overview
12.3. Market Analysis, by Indication
12.3.1. Market Value Share Analysis, by Indication
12.3.2. Market Size (US$ Mn) Forecast, by Indication
12.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.3.2.2. Primary Humoral Immunodeficiency
12.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.3.2.4. Guillain-Barre Syndrome
12.3.2.5. Myasthenia Gravis
12.3.2.6. Multifocal Motor Neuropathy (MMN)
12.3.2.7. Kawasaki Disease
12.3.2.8. Hypogammaglobulinemia
12.3.2.9. Chronic Lymphocytic Leukemia
12.3.2.10. Others
12.4. Market Analysis, by End-user
12.4.1. Market Value Share Analysis, by End-user
12.4.2. Market Size (US$ Mn) Forecast, by End-user
12.4.2.1. Hospitals
12.4.2.2. Clinics
12.4.2.3. Home Care
12.5. Market Analysis, by Country/Sub-region
12.5.1. Market Value Share Analysis, by Country/Sub-region
12.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
12.5.2.1. Brazil
12.5.2.2. Mexico
12.5.2.3. Rest of LATAM
12.6. Market Attractiveness Analysis
12.6.1. By Indication
12.6.2. By End-user
12.6.3. By Country/Sub-region
12.7. Brazil Intravenous Immunoglobulin (IVIG) Market Analysis
12.7.1. Market Size (US$ Mn) Forecast, by Indication
12.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.7.1.2. Primary Humoral Immunodeficiency
12.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.7.1.4. Guillain-Barre Syndrome
12.7.1.5. Myasthenia Gravis
12.7.1.6. Multifocal Motor Neuropathy (MMN)
12.7.1.7. Kawasaki Disease
12.7.1.8. Hypogammaglobulinemia
12.7.1.9. Chronic Lymphocytic Leukemia
12.7.1.10. Others
12.7.2. Market Size (US$ Mn) Forecast, by End-user
12.7.2.1. Hospitals
12.7.2.2. Clinics
12.7.2.3. Home Care Settings
12.8. Mexico Intravenous Immunoglobulin (IVIG) Market Analysis
12.8.1. Market Size (US$ Mn) Forecast, by Indication
12.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.8.1.2. Primary Humoral Immunodeficiency
12.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.8.1.4. Guillain-Barre Syndrome
12.8.1.5. Myasthenia Gravis
12.8.1.6. Multifocal Motor Neuropathy (MMN)
12.8.1.7. Kawasaki Disease
12.8.1.8. Hypogammaglobulinemia
12.8.1.9. Chronic Lymphocytic Leukemia
12.8.1.10. Others
12.8.2. Market Size (US$ Mn) Forecast, by End-user
12.8.2.1. Hospitals
12.8.2.2. Clinics
12.8.2.3. Home Care Settings
12.9. Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.9.1. Market Size (US$ Mn) Forecast, by Indication
12.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.9.1.2. Primary Humoral Immunodeficiency
12.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.9.1.4. Guillain-Barre Syndrome
12.9.1.5. Myasthenia Gravis
12.9.1.6. Multifocal Motor Neuropathy (MMN)
12.9.1.7. Kawasaki Disease
12.9.1.8. Hypogammaglobulinemia
12.9.1.9. Chronic Lymphocytic Leukemia
12.9.1.10. Others
12.9.2. Market Size (US$ Mn) Forecast, by End-user
12.9.2.1. Hospitals
12.9.2.2. Clinics
12.9.2.3. Home Care Settings
Section 13. Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.1. Key Findings
13.2. Market Overview
13.3. Market Analysis, by Indication
13.3.1. Market Value Share Analysis, by Indication
13.3.2. Market Size (US$ Mn) Forecast, by Indication
13.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.3.2.2. Primary Humoral Immunodeficiency
13.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.3.2.4. Guillain-Barre Syndrome
13.3.2.5. Myasthenia Gravis
13.3.2.6. Multifocal Motor Neuropathy (MMN)
13.3.2.7. Kawasaki Disease
13.3.2.8. Hypogammaglobulinemia
13.3.2.9. Chronic Lymphocytic Leukemia
13.3.2.10. Others
13.4. Market Analysis, by End-user
13.4.1. Market Value Share Analysis, by End-user
13.4.2. Market Size (US$ Mn) Forecast, by End-user
13.4.2.1. Hospitals
13.4.2.2. Clinics
13.4.2.3. Home Care
13.5. Market Analysis, by Country/Sub-region
13.5.1. Market Value Share Analysis, by Country/Sub-region
13.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
13.5.2.1. GCC Countries
13.5.2.2. South Africa
13.5.2.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Indication
13.6.2. By End-user
13.6.3. By Country/Sub-region
13.7. GCC Countries Intravenous Immunoglobulin (IVIG) Market Analysis
13.7.1. Market Size (US$ Mn) Forecast, by Indication
13.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.7.1.2. Primary Humoral Immunodeficiency
13.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.7.1.4. Guillain-Barre Syndrome
13.7.1.5. Myasthenia Gravis
13.7.1.6. Multifocal Motor Neuropathy (MMN)
13.7.1.7. Kawasaki Disease
13.7.1.8. Hypogammaglobulinemia
13.7.1.9. Chronic Lymphocytic Leukemia
13.7.1.10. Others
13.7.2. Market Size (US$ Mn) Forecast, by End-user
13.7.2.1. Hospitals
13.7.2.2. Clinics
13.7.2.3. Home Care Settings
13.8. South Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.8.1. Market Size (US$ Mn) Forecast, by Indication
13.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.8.1.2. Primary Humoral Immunodeficiency
13.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.8.1.4. Guillain-Barre Syndrome
13.8.1.5. Myasthenia Gravis
13.8.1.6. Multifocal Motor Neuropathy (MMN)
13.8.1.7. Kawasaki Disease
13.8.1.8. Hypogammaglobulinemia
13.8.1.9. Chronic Lymphocytic Leukemia
13.8.1.10. Others
13.8.2. Market Size (US$ Mn) Forecast, by End-user
13.8.2.1. Hospitals
13.8.2.2. Clinics
13.8.2.3. Home Care Settings
13.9. Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.9.1. Market Size (US$ Mn) Forecast, by Indication
13.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.9.1.2. Primary Humoral Immunodeficiency
13.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.9.1.4. Guillain-Barre Syndrome
13.9.1.5. Myasthenia Gravis
13.9.1.6. Multifocal Motor Neuropathy (MMN)
13.9.1.7. Kawasaki Disease
13.9.1.8. Hypogammaglobulinemia
13.9.1.9. Chronic Lymphocytic Leukemia
13.9.1.10. Others
13.9.2. Market Size (US$ Mn) Forecast, by End-user
13.9.2.1. Hospitals
13.9.2.2. Clinics
13.9.2.3. Home Care Settings
Section 14. Company Profiles
14.1. Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2017)
14.2. Competition Matrix
14.3. Company Profiles
14.3.1. Baxalta Incorporated
Company Overview (HQ, Business Segments, Employee Strength)
Financial Overview
Product Portfolio
SWOT Analysis
Strategic Overview
14.3.2. Biotest AG
Company Overview (HQ, Business Segments, Employee Strength)
Financial Overview
Product Portfolio
SWOT Analysis
Strategic Overview
14.3.3. China Biologic Products, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Financial Overview
Product Portfolio
SWOT Analysis
Strategic Overview
14.3.4. CSL Behring LLC
Company Overview (HQ, Business Segments, Employee Strength)
Financial Overview
Product Portfolio
SWOT Analysis
Strategic Overview
14.3.5. Grifols S.A.
Company Overview (HQ, Business Segments, Employee Strength)
Financial Overview
Product Portfolio
SWOT Analysis
Strategic Overview
14.3.6. Kedrion S.p.A.
Company Overview (HQ, Business Segments, Employee Strength)
Financial Overview
Product Portfolio
SWOT Analysis
Strategic Overview
14.3.7. LFB Biomedicaments S.A.
Company Overview (HQ, Business Segments, Employee Strength)
Financial Overview
Product Portfolio
SWOT Analysis
Strategic Overview
14.3.8. Octapharma AG
Company Overview (HQ, Business Segments, Employee Strength)
Financial Overview
Product Portfolio
SWOT Analysis
Strategic Overview
14.3.9. Sanquin Plasma Products B.V.
Company Overview (HQ, Business Segments, Employee Strength)
Financial Overview
Product Portfolio
SWOT Analysis
Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers